Who
Alan M. Garber
Director
Company insider
Files Form 4 as: Director, Vertex Pharmaceuticals; Director, Exelixis.
In numbers
- Trades disclosed
- 85
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $7.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 May 2006
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15K29.272 at $512.44 | filing |
| 15 Jul 2026filed 17 Jul 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15K31.56 at $475.28 | filing |
| 15 Jul 2026filed 17 Jul 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15K31.56 at $475.28 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —472 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,433 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,433 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —472 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15K33.898 at $442.50 | filing |
| 15 Apr 2026filed 17 Apr 2026 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15K33.9 at $442.50 | filing |
| 1 May 2025filed 5 May 2025 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,199 at $0.00 | filing |
| 1 May 2025filed 5 May 2025 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —398 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,142 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,491 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $460K23,491 at $19.57 | filing |
| 21 Mar 2024filed 25 Mar 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $461K19,205 at $24.01 | filing |
| 1 Jun 2023filed 2 Jun 2023 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,087 at $0.00 | filing |
| 1 May 2023filed 3 May 2023 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,741 at $0.00 | filing |
| 1 May 2023filed 3 May 2023 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —584 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $252K40,000 at $6.30 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Alan M. Garber; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.